midodrine has been researched along with Tachycardia in 7 studies
Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.
Tachycardia: Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.
Excerpt | Relevance | Reference |
---|---|---|
"We assessed the potency of octreotide and midodrine, and their combination, in the treatment of the postural tachycardia syndrome (POTS) and orthostatic intolerance (OI)." | 9.12 | Treatment of postural tachycardia syndrome: a comparison of octreotide and midodrine. ( Bryner, KD; Hobbs, G; Hoeldtke, ME; Hoeldtke, RD, 2006) |
" POTS subjects received 2 weeks of treatment with midodrine or placebo, with increased dosing from 2." | 6.79 | A double-blind placebo-controlled cross-over study of the vascular effects of midodrine in neuropathic compared with hyperadrenergic postural tachycardia syndrome. ( Medow, MS; Ocon, AJ; Ross, AJ; Stewart, JM, 2014) |
" Midodrine did not cause any untoward reactions in these subjects before or after flight; in fact, a modest beneficial effect was seen on postflight tachycardia (p = 0." | 5.12 | Hemodynamic effects of midodrine after spaceflight in astronauts without orthostatic hypotension. ( Meck, JV; Platts, SH; Waters, WW; Ziegler, MG, 2006) |
"We assessed the potency of octreotide and midodrine, and their combination, in the treatment of the postural tachycardia syndrome (POTS) and orthostatic intolerance (OI)." | 5.12 | Treatment of postural tachycardia syndrome: a comparison of octreotide and midodrine. ( Bryner, KD; Hobbs, G; Hoeldtke, ME; Hoeldtke, RD, 2006) |
" POTS subjects received 2 weeks of treatment with midodrine or placebo, with increased dosing from 2." | 2.79 | A double-blind placebo-controlled cross-over study of the vascular effects of midodrine in neuropathic compared with hyperadrenergic postural tachycardia syndrome. ( Medow, MS; Ocon, AJ; Ross, AJ; Stewart, JM, 2014) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (14.29) | 18.2507 |
2000's | 5 (71.43) | 29.6817 |
2010's | 1 (14.29) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ross, AJ | 1 |
Ocon, AJ | 1 |
Medow, MS | 1 |
Stewart, JM | 1 |
Cheshire, WP | 1 |
Achem, SR | 1 |
Honma, K | 1 |
Platts, SH | 1 |
Ziegler, MG | 1 |
Waters, WW | 1 |
Meck, JV | 1 |
Hoeldtke, RD | 1 |
Bryner, KD | 1 |
Hoeldtke, ME | 1 |
Hobbs, G | 1 |
Jacob, G | 1 |
Shannon, JR | 1 |
Black, B | 1 |
Biaggioni, I | 1 |
Mosqueda-Garcia, R | 1 |
Robertson, RM | 1 |
Robertson, D | 1 |
Gordon, VM | 1 |
Opfer-Gehrking, TL | 1 |
Novak, V | 1 |
Low, PA | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Gabapentin Treatment of Postural Tachycardia Syndrome (PoTS): a Pilot Study[NCT04345432] | 10 participants (Actual) | Interventional | 2014-01-31 | Completed | |||
A Double-Blinded, Placebo-Controlled Study To Assess Hemodynamic Changes, Orthostatic Tolerance, Out-Patient Fatigue And Quality Of Life In Neuropathic And Non-Neuropathic POTS Patients In Response To Adrenoreceptor Agonist And Antagonist[NCT03070730] | Phase 1/Phase 2 | 8 participants (Actual) | Interventional | 2011-08-15 | Terminated (stopped due to Recruitment was slow and subjects declined participation after signing the ICF.) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
(NCT03070730)
Timeframe: 1 week after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after third intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: 2 weeks after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: 2 weeks after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: up to 3 days after randomization
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after third intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: Up to 3 days after randomization
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after third intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after third intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after third intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after third intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after third intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after third intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after third intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after third intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
1 review available for midodrine and Tachycardia
Article | Year |
---|---|
[Diabetes mellitus and orthostatic intolerance].
Topics: Bandages; Diabetic Neuropathies; Diet, Sodium-Restricted; Exercise Therapy; Heart Rate; Humans; Male | 2005 |
4 trials available for midodrine and Tachycardia
Article | Year |
---|---|
A double-blind placebo-controlled cross-over study of the vascular effects of midodrine in neuropathic compared with hyperadrenergic postural tachycardia syndrome.
Topics: Adolescent; Adult; Blood Pressure; Child; Cross-Over Studies; Double-Blind Method; Female; Heart Rat | 2014 |
Hemodynamic effects of midodrine after spaceflight in astronauts without orthostatic hypotension.
Topics: Adrenergic alpha-Agonists; Astronauts; Blood Pressure; Cardiac Output; Hemodynamics; Humans; Hypoten | 2006 |
Treatment of postural tachycardia syndrome: a comparison of octreotide and midodrine.
Topics: Adult; Blood Pressure; Data Interpretation, Statistical; Dizziness; Drug Therapy, Combination; Femal | 2006 |
Effects of volume loading and pressor agents in idiopathic orthostatic tachycardia.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Blood Pressure; Blood Volume; Clonidine; Female; Heart | 1997 |
2 other studies available for midodrine and Tachycardia
Article | Year |
---|---|
Clinical history.
Topics: Blood Pressure; Chest Pain; Clonazepam; Female; Heart Rate; Humans; Hypertension; Incidence; Middle | 2004 |
Hemodynamic and symptomatic effects of acute interventions on tilt in patients with postural tachycardia syndrome.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Antihypertensive Agents; Clonidine; Female; Hemodynamics; | 2000 |